Literature DB >> 30945291

NLRC5 negatively regulates LTA-induced inflammation via TLR2/NF-κB and participates in TLR2-mediated allergic airway inflammation.

Muzi Wang1, Lixia Wang1, Lei Fang1, Shuai Li2, Rongyu Liu1.   

Abstract

NLRC5, the largest member of the Nod-like receptor (NLR) family, has been reported to play a pivotal role in regulating inflammatory responses. Recent evidence suggests that NLRC5 participates in Toll-like receptor (TLR) signaling pathways and negatively modulates nuclear factor-κB (NF-κB) activation. In this study, we investigated the interaction between NLRC5 and TLR2 in the NF-κB inflammatory signaling pathway and the involvement of NLRC5 in TLR2-mediated allergic airway inflammation. We knocked down TLR2 and NLRC5, respectively in the RAW264.7 macrophage cell line by small interfering RNA (siRNA) and then stimulated the knockdown cells with lipoteichoic acid (LTA). In comparison with the negative siRNA group, the level of NLRC5 expression was lower in the TLR2 siRNA group, with a reduction in the NF-κB-related inflammatory response. Conversely, in the NLRC5 knockdown cells, after LTA-treated the level of TLR2 expression did not change but the expression levels of both NF-κB pp65 and NLRP3 increased remarkably. Thus, we hypothesize that NLRC5 participates in the LTA-induced inflammatory signaling pathway and regulates the inflammation via TLR2/NF-κB. Similarly, in subsequent in vivo experiments, we demonstrated that the expression level of NLRC5 was significantly increased in the ovalbumin-induced allergic airway inflammation. However, this effect disappeared in TLR2-deficient (TLR2 -/- ) mice and was accompanied by reduced levels of NF-κB expression and airway inflammation. In conclusion, NLRC5 negatively regulates LTA-induced inflammatory response via a TLR2/NF-κB pathway in macrophages and also participates in TLR2-mediated allergic airway inflammation.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  NLRC5; TLR2; allergic airway inflammation; macrophage; negative regulation

Mesh:

Substances:

Year:  2019        PMID: 30945291     DOI: 10.1002/jcp.28596

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  The USP14-NLRC5 pathway inhibits titanium particle-induced osteolysis in mice by suppressing NF-κB and PI3K/AKT activities.

Authors:  Guibin Fang; Yuan Fu; Shixun Li; Junxiong Qiu; Manyuan Kuang; Sipeng Lin; Changchuan Li; Yue Ding
Journal:  J Biol Chem       Date:  2020-04-09       Impact factor: 5.157

Review 2.  Insights into inflammasome regulation: cellular, molecular, and pathogenic control of inflammasome activation.

Authors:  Naveen Challagundla; Bhaskar Saha; Reena Agrawal-Rajput
Journal:  Immunol Res       Date:  2022-05-24       Impact factor: 4.505

Review 3.  MHC class I transactivator NLRC5 in host immunity, cancer and beyond.

Authors:  Steven X Cho; Saptha Vijayan; Ji-Seung Yoo; Toshiyuki Watanabe; Ryota Ouda; Ning An; Koichi S Kobayashi
Journal:  Immunology       Date:  2020-08-03       Impact factor: 7.397

4.  NLRC5 attenuates inflammatory response in IL-1β-stimulated human osteoarthritis chondrocytes through the NF-κB signaling pathway.

Authors:  Yiping Mu; Yang Zhang; Jie Wu; Qi Li
Journal:  Aging (Albany NY)       Date:  2021-08-26       Impact factor: 5.682

5.  A. caviae infection triggers IL-1β secretion through activating NLRP3 inflammasome mediated by NF-κB signaling pathway partly in a TLR2 dependent manner.

Authors:  Qiankun Yang; Jianguo Zhang; Feixue Liu; Huizhen Chen; Wei Zhang; Haitao Yang; Nana He; Jingquan Dong; Panpan Zhao
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

6.  NLRC5 alleviated OGD/R-induced PC12-cell injury by inhibiting activation of the TLR4/MyD88/NF-κB pathway.

Authors:  Zhen Zhang; Yuhan Sun; Xin Chen
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

7.  TLR2-Melatonin Feedback Loop Regulates the Activation of NLRP3 Inflammasome in Murine Allergic Airway Inflammation.

Authors:  Hui-Mei Wu; Cui-Cui Zhao; Qiu-Meng Xie; Juan Xu; Guang-He Fei
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.